Table 1.

Characteristics of 18 studies.

	Author, year	ID	Trial phase	Masking	Total N	Follow-up time (mo)	Inventions	Analyzed patients	CTCAE version	Discontinuation*
NSCLC
1	(Brahmer et al., 2015)	Checkmate017	III	Open-label	272	UK	Nivolumab 3 mg/kg q 2 weeks	135	4.0	4
							docetaxel 75 mg/m2 q 3 weeks	137		13
2	(Govindan et al., 2017)	Checkmate026	III	Open-label	541		Nivolumab 3 mg/kg q 2 weeks	267	4.0	26
						UK	Platinum-based chemotherapy q3 weeks	263		35
3	(Borghaei et al., 2015)	Checkmate057	III	Open-label	582	14.5	Nivolumab 3 mg/kg q 2 weeks	287	4.0	14
							Docetaxel 75 mg/m2 q 3 weeks	268		40
4	(Rittmeyer et al., 2017)	OAK	III	Open-label	850	21	atezolizumab 1,200 mg	425	4.0	46
							docetaxel 75 mg/m2 q 3 weeks	425		108
5	(Fehrenbacher et al., 2016)	POPLAR	II	Open-label	287	14.8	Atezolizumab 1,200 mg	144		2
							Docetaxel 75 mg/m2 q 3 weeks	143		24
6	(Socinski et al., 2018)	IMPOWER150	III	Open-label	787	15.4	Atezolizumab + bevacizumab + carboplatin plus paclitaxel (ABCP)	393	4.0	128
							Bevacizumab + carboplatin + paclitaxel (BCP group)	394		98
7	(Herbst et al., 2016)	Keynote010	II/III	Open-label	1,034	10.4	Pembrolizumab 2 mg/kg q 3 weeks	339	4	15
							Pembrolizumab 10 mg/kg q 3 weeks	343		17
							Docetaxel 75 mg/m2 q 3 weeks	309		31
8	(Gandhi et al., 2018)	Keynote189	III	Double-blind	616	10.5	Pembrolizumab + pemetrexed + platinum-based drug	405	4	112
							Placebo + pemetrexed + Platinum-based drug	202		30
9	(Paz-Ares et al., 2018)	Keynote407	III	Double-blind	559	7.8	Pembrolizumab 200 mg + chemotherapy	278	4.03	37
							Placebo + chemotherapy	280		34
10	(Antonia et al., 2017)	PACIFIC	III	Double-blind	713	14.5	Durvalumab 10 mg/kg q 2 weeks	475	4.03	73
							Placebo	234		23
11	(Barlesi et al., 2018)	JAVELIN Lung 200	III	Open-label	792	18.3	Avelumab 10 mg/kg q 2 weeks	393	4.03	28
							Docetaxel 75 mg/m² q 3 weeks	365		51
Melanoma
12	(Larkin et al., 2018)	Checkmate037	III	Open-label	405	24	Nivolumab 3 mg/kg q 2 weeks	268	4.0	13
							Chemotherapy	102		11
13	(Robert et al., 2015)	Checkmate066	III	Double-blind	418	16.7	Nivolumab 3 mg/kg q 2 weeks	206	4.0	14
							Dacarbazine 1,000 mg/m2 q 3 weeks	205		24
14	(Larkin et al., 2015)	Checkmate067	III	Double-blind	945	9	Nivolumab 1 mg/kg + ipilimumab 3 mg/kg	313	4.0	24
							Nivolumab 3 mg/kg q 2 weeks	313		114
							Ipilimumab 3 mg/kg q 3 weeks	311		46
15	(Postow et al., 2015)	Checkmate069	II	Double-blind	142	24.6	Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg	94	4.0	44
							Ipilimumab 3 mg/kg q 3 weeks	46		8
16	(Weber et al., 2017)	Checkmate238	III	Double-blind	906	19.5	Nivolumab 3 mg/kg q 2 weeks	452	4.0	35
							Ipilimumab 10 mg/kg q 3 weeks	453		189
17	(Ribas et al., 2015)	Keynote 002	II	Double-blind	540	10	Pembrolizumab 2 mg/kg q 3 weeks	180	4.0	4
							Pembrolizumab 10 mg/kg q 3 weeks	181		13
							Chemotherapy	179		10
18	(Schachter et al., 2017)	Keynote006	III	Open-label	834	22.9	Pembrolizumab 10 mg/kg, q 2 weeks	278	4.0	19
							Pembrolizumab 10 mg/kg, q 3 weeks	277		30
							Ipilimumab q 3 weeks	256		23

*Discontinuation for treatment-related Aes CTCAE, Common Terminology Criteria for Adverse Events; UK, unknown; q 2 weeks, every 2 weeks; q 3 weeks, every 3 weeks.